Insiders who reported open-market trades in the last 12 months at the companies Robin Shane Readnour files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Joshua M. Eizen - $53K in ANTX purchases and sales in the last 12 months
Robin Shane Readnour is a corporate insider, tracked as Director of AN2 Therapeutics, Inc. (ANTX). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Robin Shane Readnour submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Robin Shane Readnour been buying or selling stock?
Recorded transactions: 14 open-market purchases ($406K) and 8 open-market sales ($317K) across all tracked filings.
Robin Shane Readnour is Director of AN2 Therapeutics, Inc. (ANTX). 9 SEC Form 4 filings on record going back to 2024, most recently on 11 September 2026. Most recent open-market trade: sold $4K of ANTX on 11 September 2026. Lifetime open-market purchases: $406K. Lifetime open-market sales: $317K.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Robin Shane Readnour.
InsiderAlpha's records for Robin Shane Readnour go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $29K (14 buys totaling $406K). The largest single buy on record is $78K of ANTX in 2024. Sales side: 8 recorded sales totaling $317K, so the filing history runs buy-heavy by dollar value. 8 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
